Antibody sequence-based prediction of pH gradient elution in multimodal chromatography.

Downstream manufacturability assessment In silico process development Multispecific monoclonal antibody (mAb) formats Quantitative structure-activity/property relationship (QSAR/QSPR) Structure-function analysis

Journal

Journal of chromatography. A
ISSN: 1873-3778
Titre abrégé: J Chromatogr A
Pays: Netherlands
ID NLM: 9318488

Informations de publication

Date de publication:
22 Nov 2023
Historique:
received: 11 07 2023
revised: 03 10 2023
accepted: 05 10 2023
medline: 6 11 2023
pubmed: 22 10 2023
entrez: 21 10 2023
Statut: ppublish

Résumé

Multimodal chromatography has emerged as a promising technique for antibody purification, owing to its capacity to selectively capture and separate target molecules. However, the optimization of chromatography parameters remains a challenge due to the intricate nature of protein-ligand interactions. To tackle this issue, efficient predictive tools are essential for the development and optimization of multimodal chromatography processes. In this study, we introduce a methodology that predicts the elution behavior of antibodies in multimodal chromatography based on their amino acid sequences. We analyzed a total of 64 full-length antibodies, including IgG1, IgG4, and IgG-like multispecific formats, which were eluted using linear pH gradients from pH 9.0 to 4.0 on the anionic mixed-mode resin Capto adhere. Homology models were constructed, and 1312 antibody-specific physicochemical descriptors were calculated for each molecule. Our analysis identified six key structural features of the multimodal antibody interaction, which were correlated with the elution behavior, emphasizing the antibody variable region. The results show that our methodology can predict pH gradient elution for a diverse range of antibodies and antibody formats, with a test set R² of 0.898. The developed model can inform process development by predicting initial conditions for multimodal elution, thereby reducing trial and error during process optimization. Furthermore, the model holds the potential to enable an in silico manufacturability assessment by screening target antibodies that adhere to standardized purification conditions. In conclusion, this study highlights the feasibility of using structure-based prediction to enhance antibody purification in the biopharmaceutical industry. This approach can lead to more efficient and cost-effective process development while increasing process understanding.

Identifiants

pubmed: 37865026
pii: S0021-9673(23)00662-3
doi: 10.1016/j.chroma.2023.464437
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Immunoglobulin G 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

464437

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Rudger Hess (R)

Institute of Engineering in Life Sciences, Section IV: Biomolecular Separation Engineering, Karlsruhe Institute of Technology (KIT), Karlsruhe, Germany; DSP Development, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

Jan Faessler (J)

DSP Development, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

Doil Yun (D)

DSP Development, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

David Saleh (D)

DSP Development, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

Jan-Hendrik Grosch (JH)

DSP Development, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

Thomas Schwab (T)

DSP Development, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

Jürgen Hubbuch (J)

Institute of Engineering in Life Sciences, Section IV: Biomolecular Separation Engineering, Karlsruhe Institute of Technology (KIT), Karlsruhe, Germany. Electronic address: juergen.hubbuch@kit.edu.

Articles similaires

Humans COVID-19 Immunoglobulin G Antibodies, Viral SARS-CoV-2
Humans Amyotrophic Lateral Sclerosis Male Middle Aged Female
Humans Malaria, Vivax Plasmodium vivax Antibodies, Protozoan Adult
Humans Neuromyelitis Optica Female Male Middle Aged

Classifications MeSH